Leap Book Value Per Share from 2010 to 2025

LPTX Stock

USD 0.48 0.01 2.04%

Leap Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 3.21 in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Leap Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

3.38

Current Value

3.21

Quarterly Volatility

9.99231766

Credit Downgrade

Yuan Drop

Covid

Check Leap Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Leap Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 336.9 K, Interest Expense of 4.3 K or Selling General Administrative of 8.7 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0025 or PTB Ratio of 1.41. Leap financial statements analysis is a perfect complement when working with Leap Therapeutics Valuation or Volatility modules.

Check out the analysis of Leap Therapeutics Correlation against competitors.

For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Latest Leap Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Leap Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Leap Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Leap Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.28 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Leap Book Value Per Share Regression Statistics

	Arithmetic Mean	12.36
	Coefficient Of Variation	80.81
	Mean Deviation	7.34
	Median	12.13
	Standard Deviation	9.99
	Sample Variance	99.85
	Range	39.7272
	R-Value	(0.71)
	Mean Square Error	53.37
	R-Squared	0.50
	Significance	0
	Slope	(1.49)
	Total Sum of Squares	1,498

Leap Book Value Per Share History

	2025	3.21
	2024	3.38
	2023	2.94
	2022	5.2
	2021	12.57
	2020	7.86
	2019	-0.77

Other Fundumenentals of Leap Therapeutics

Tangible Book Value Per Share

Leap Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Short Term Debt	Current Deferred Revenue	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.81	-0.92	-0.71	0.52	0.11	0.42	1.0	0.3	0.71	0.05	-0.36	0.41	0.74	-0.43	0.96	0.95	0.72
Total Stockholder Equity	0.81		-0.9	-0.57	0.37	-0.35	0.24	0.82	0.76	0.81	0.21	-0.79	0.14	0.67	-0.4	0.73	0.71	0.6
Net Debt	-0.92	-0.9		0.73	-0.56	0.03	-0.45	-0.92	-0.49	-0.88	-0.09	0.56	-0.42	-0.81	0.54	-0.93	-0.91	-0.76
Retained Earnings	-0.71	-0.57	0.73		-0.94	-0.26	-0.67	-0.7	-0.15	-0.62	-0.48	0.29	-0.79	-0.96	0.68	-0.75	-0.66	-0.62
Accounts Payable	0.52	0.37	-0.56	-0.94		0.38	0.7	0.51	0.0	0.54	0.55	-0.15	0.84	0.92	-0.67	0.61	0.51	0.51
Net Receivables	0.11	-0.35	0.03	-0.26	0.38		0.44	0.11	-0.72	-0.17	-0.13	0.63	0.55	0.2	-0.23	0.2	0.22	0.27
Total Liab	0.42	0.24	-0.45	-0.67	0.7	0.44		0.42	0.09	0.49	0.2	-0.25	0.81	0.69	-0.85	0.44	0.38	0.31
Total Current Assets	1.0	0.82	-0.92	-0.7	0.51	0.11	0.42		0.3	0.7	0.04	-0.36	0.4	0.74	-0.42	0.96	0.95	0.71
Common Stock	0.3	0.76	-0.49	-0.15	0.0	-0.72	0.09	0.3		0.59	0.24	-0.98	-0.19	0.26	-0.28	0.17	0.14	0.17
Net Tangible Assets	0.71	0.81	-0.88	-0.62	0.54	-0.17	0.49	0.7	0.59		0.22	-0.67	0.37	0.76	-0.55	0.75	0.71	0.64
Property Plant Equipment	0.05	0.21	-0.09	-0.48	0.55	-0.13	0.2	0.04	0.24	0.22		-0.29	0.21	0.42	-0.06	0.04	-0.06	0.1
Short Term Debt	-0.36	-0.79	0.56	0.29	-0.15	0.63	-0.25	-0.36	-0.98	-0.67	-0.29		0.01	-0.4	0.43	-0.25	-0.2	-0.24
Current Deferred Revenue	0.41	0.14	-0.42	-0.79	0.84	0.55	0.81	0.4	-0.19	0.37	0.21	0.01		0.78	-0.82	0.51	0.4	0.5
Capital Surpluse	0.74	0.67	-0.81	-0.96	0.92	0.2	0.69	0.74	0.26	0.76	0.42	-0.4	0.78		-0.75	0.8	0.71	0.71
Deferred Long Term Liab	-0.43	-0.4	0.54	0.68	-0.67	-0.23	-0.85	-0.42	-0.28	-0.55	-0.06	0.43	-0.82	-0.75		-0.45	-0.36	-0.44
Net Invested Capital	0.96	0.73	-0.93	-0.75	0.61	0.2	0.44	0.96	0.17	0.75	0.04	-0.25	0.51	0.8	-0.45		0.99	0.78
Net Working Capital	0.95	0.71	-0.91	-0.66	0.51	0.22	0.38	0.95	0.14	0.71	-0.06	-0.2	0.4	0.71	-0.36	0.99		0.74
Capital Stock	0.72	0.6	-0.76	-0.62	0.51	0.27	0.31	0.71	0.17	0.64	0.1	-0.24	0.5	0.71	-0.44	0.78	0.74

Click cells to compare fundamentals

About Leap Therapeutics Financial Statements

Leap Therapeutics investors use historical fundamental indicators, such as Leap Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Leap Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	3.38	3.21
Tangible Book Value Per Share	3.38	3.21

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC